GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » PURE Bioscience Inc (OTCPK:PURE) » Definitions » Cyclically Adjusted Revenue per Share

PURE Bioscience (PURE Bioscience) Cyclically Adjusted Revenue per Share : $0.04 (As of Jan. 2024)


View and export this data going back to 1996. Start your Free Trial

What is PURE Bioscience Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

PURE Bioscience's adjusted revenue per share for the three months ended in Jan. 2024 was $0.003. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.04 for the trailing ten years ended in Jan. 2024.

During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was -12.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was -19.30% per year. During the past 10 years, the average Cyclically Adjusted Revenue Growth Rate was -15.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of PURE Bioscience was 38.70% per year. The lowest was -60.70% per year. And the median was -20.55% per year.

As of today (2024-04-28), PURE Bioscience's current stock price is $0.071. PURE Bioscience's Cyclically Adjusted Revenue per Share for the quarter that ended in Jan. 2024 was $0.04. PURE Bioscience's Cyclically Adjusted PS Ratio of today is 1.78.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PURE Bioscience was 32.00. The lowest was 1.68. And the median was 5.38.


PURE Bioscience Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for PURE Bioscience's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PURE Bioscience Cyclically Adjusted Revenue per Share Chart

PURE Bioscience Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.09 0.06 0.06 0.04 0.04

PURE Bioscience Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.04 0.04 0.04 0.04 0.04

Competitive Comparison of PURE Bioscience's Cyclically Adjusted Revenue per Share

For the Household & Personal Products subindustry, PURE Bioscience's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PURE Bioscience's Cyclically Adjusted PS Ratio Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, PURE Bioscience's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where PURE Bioscience's Cyclically Adjusted PS Ratio falls into.



PURE Bioscience Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, PURE Bioscience's adjusted Revenue per Share data for the three months ended in Jan. 2024 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jan. 2024 (Change)*Current CPI (Jan. 2024)
=0.003/129.4194*129.4194
=0.003

Current CPI (Jan. 2024) = 129.4194.

PURE Bioscience Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201404 0.009 100.023 0.012
201407 0.005 100.520 0.006
201410 0.003 100.176 0.004
201501 0.007 98.604 0.009
201504 0.003 99.824 0.004
201507 0.006 100.691 0.008
201510 0.004 100.346 0.005
201601 0.003 99.957 0.004
201604 0.006 100.947 0.008
201607 0.008 101.524 0.010
201610 0.008 101.988 0.010
201701 0.007 102.456 0.009
201704 0.005 103.167 0.006
201707 0.008 103.278 0.010
201710 0.007 104.070 0.009
201801 0.006 104.578 0.007
201804 0.006 105.708 0.007
201807 0.007 106.324 0.009
201810 0.008 106.695 0.010
201901 0.006 106.200 0.007
201904 0.004 107.818 0.005
201907 0.008 108.250 0.010
201910 0.005 108.577 0.006
202001 0.004 108.841 0.005
202004 0.026 108.173 0.031
202007 0.041 109.318 0.049
202010 0.018 109.861 0.021
202101 0.011 110.364 0.013
202104 0.006 112.673 0.007
202107 0.010 115.183 0.011
202110 0.006 116.696 0.007
202201 0.005 118.619 0.005
202204 0.006 121.978 0.006
202207 0.004 125.002 0.004
202210 0.004 125.734 0.004
202301 0.004 126.223 0.004
202304 0.004 127.992 0.004
202307 0.005 128.974 0.005
202310 0.006 129.810 0.006
202401 0.003 129.419 0.003

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


PURE Bioscience  (OTCPK:PURE) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

PURE Bioscience's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=0.071/0.04
=1.78

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of PURE Bioscience was 32.00. The lowest was 1.68. And the median was 5.38.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


PURE Bioscience Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of PURE Bioscience's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


PURE Bioscience (PURE Bioscience) Business Description

Traded in Other Exchanges
N/A
Address
771 Jamacha Road, No. 512, El Cajon, CA, USA, 92019
PURE Bioscience Inc is engaged in developing and commercializing proprietary antimicrobial products. The company's technology platform is based on patented stabilized ionic silver, and its initial products contain silver dihydrogen citrate, or SDC. It offers PURE Hard Surface as a food contact surface sanitizer and disinfectant to restaurant chains, food processors and food transportation companies and PURE Control as a direct food contact processing aid. It also manufactures and sells SDC-based products for end use, products preserved with SDC and SDC as a raw material ingredient for manufacturing use.
Executives
Robert F Bartlett director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Bernard Blotner director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Tom Y Lee director 1807 SAN GABRIEL BLVD., SAN GABRIEL CA 91776
David Rendall director 9669 HERMOSA AVENUE, RANCHO CUCAMONGA CA 91730
Kristin Taylor director 13500 EVENING CREEK DRIVE N, SUITE 550, SAN DIEGO CA 92128
Dale Okuno director 35 N. ARROYO PARKWAY, SUITE 1, PASADENA CA 91103
Ivan Chen director 1725 GILLESPIE WAY, EL CAJON CA 92020
Thomas Richard Myers officer: Chief Operating Officer 1725 GILLESPIE WAY, EL CAJON CA 92130
Henry R. Lambert director, officer: Chief Executive Officer 1725 GILLESPIE WAY, EL CAJON CA 92020
Elisabeth Hagen director 1725 GILLESPIE WAY, EL CAJON CA 92020
Janet Risi Field director 9200 SOUTH DADELAND BOULEVARD, SUITE 800, MIAMI FL 33156
Franchise Brands, Llc 10 percent owner 325 BIC DRIVE, MILFORD CT 06461
Mark Stuart Elliott officer: Vice President, Finance 1725 GILLESPIE WAY, EL CAJON CA 92020
William Otis director 1725 GILLESPIE WAY, EL CAJON CA 92020
David M Theno director 1725 GILLESPIE WAY, EL CAJON CA 92020